Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating JZP150 for Once-Daily Treatment of Adults with Post-Traumatic Stress Disorder
Ryan Allway December 30th, 2021 U.S. FDA granted JZP150 Fast Track designation in PTSD, underscoring the unmet needs of patients If approved, JZP150 would become the first new drug approved in 20 years for patients with PTSD; topline data readout anticipated by the end of 2023 DUBLIN, Dec. 30, 2021 /PRNewswire/... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )